These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 24178238)

  • 1. Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects.
    Cawello W; Kim SR; Braun M; Elshoff JP; Ikeda J; Funaki T
    Clin Drug Investig; 2014 Feb; 34(2):95-105. PubMed ID: 24178238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, safety, and tolerability of rotigotine transdermal system in healthy Japanese and Caucasian subjects following multiple-dose administration.
    Cawello W; Kim SR; Braun M; Elshoff JP; Masahiro T; Ikeda J; Funaki T
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):353-62. PubMed ID: 25773763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, Tolerability, and Bioequivalence of Two Formulations of Rotigotine in Healthy Chinese Subjects.
    Liu Y; Tomlinson B; Guo J; Asgharnejad M; Bauer L; Surmann E; Guo X; Elshoff JP
    Clin Ther; 2018 Jul; 40(7):1108-1121.e8. PubMed ID: 30098648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome.
    Elshoff JP; Cawello W; Andreas JO; Mathy FX; Braun M
    Drugs; 2015 Apr; 75(5):487-501. PubMed ID: 25795100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic properties and tolerability of rotigotine transdermal patch after repeated-dose application in healthy korean volunteers.
    Kim BH; Yu KS; Jang IJ; Soo Lim K; Kim JR; Elshoff JP; Andreas JO; Braun M; Cawello W
    Clin Ther; 2015 Apr; 37(4):902-12. PubMed ID: 25791613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of hepatic impairment on the pharmacokinetics of the dopamine agonist rotigotine.
    Cawello W; Fichtner A; Boekens H; Braun M
    Eur J Drug Metab Pharmacokinet; 2014 Sep; 39(3):155-63. PubMed ID: 24052490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single dose pharmacokinetics of the transdermal rotigotine patch in patients with impaired renal function.
    Cawello W; Ahrweiler S; Sulowicz W; Szymczakiewicz-Multanowska A; Braun M
    Br J Clin Pharmacol; 2012 Jan; 73(1):46-54. PubMed ID: 21707699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome.
    Boroojerdi B; Wolff HM; Braun M; Scheller DK
    Drugs Today (Barc); 2010 Jul; 46(7):483-505. PubMed ID: 20683503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine.
    Braun M; Cawello W; Boekens H; Horstmann R
    Br J Clin Pharmacol; 2009 Feb; 67(2):209-15. PubMed ID: 19094160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal administration of radiolabelled [14C]rotigotine by a patch formulation: a mass balance trial.
    Cawello W; Wolff HM; Meuling WJ; Horstmann R; Braun M
    Clin Pharmacokinet; 2007; 46(10):851-7. PubMed ID: 17854234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine.
    Elshoff JP; Cawello W; Andreas JO; Braun M
    Clin Pharmacol Drug Dev; 2014 May; 3(3):187-93. PubMed ID: 27128608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study.
    Oertel W; Trenkwalder C; Beneš H; Ferini-Strambi L; Högl B; Poewe W; Stiasny-Kolster K; Fichtner A; Schollmayer E; Kohnen R; García-Borreguero D;
    Lancet Neurol; 2011 Aug; 10(8):710-20. PubMed ID: 21705273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies.
    Elshoff JP; Braun M; Andreas JO; Middle M; Cawello W
    Clin Ther; 2012 Apr; 34(4):966-78. PubMed ID: 22401642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome.
    Bogan RK
    Clin Ther; 2014 Mar; 36(3):436-55. PubMed ID: 24636821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rotigotine Transdermal Patch: A Review in Restless Legs Syndrome.
    Garnock-Jones KP
    Drugs; 2016 Jul; 76(10):1031-40. PubMed ID: 27324269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch.
    Högl B; Oertel WH; Stiasny-Kolster K; Geisler P; Beneš H; García-Borreguero D; Trenkwalder C; Poewe W; Schollmayer E; Kohnen R
    BMC Neurol; 2010 Sep; 10():86. PubMed ID: 20920156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of rotigotine transdermal system in adolescents with idiopathic restless legs syndrome (Willis-Ekbom disease).
    Elshoff JP; Hudson J; Picchietti DL; Ridel K; Walters AS; Doggett K; Moran K; Oortgiesen M; Ramirez F; Schollmayer E
    Sleep Med; 2017 Apr; 32():48-55. PubMed ID: 28366342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rotigotine transdermal patch for the treatment of Parkinson's Disease.
    Perez-Lloret S; Rey MV; Ratti PL; Rascol O
    Fundam Clin Pharmacol; 2013 Feb; 27(1):81-95. PubMed ID: 22320451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rotigotine transdermal patch enables rapid titration to effective doses in advanced-stage idiopathic Parkinson disease: subanalysis of a parallel group, open-label, dose-escalation study.
    Babic T; Boothmann B; Polivka J; Rektor I; Boroojerdi B; Häck HJ; Randerath O
    Clin Neuropharmacol; 2006; 29(4):238-42. PubMed ID: 16855426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug Delivery and Transport into the Central Circulation: An Example of Zero-Order In vivo Absorption of Rotigotine from a Transdermal Patch Formulation.
    Cawello W; Braun M; Andreas JO
    Eur J Drug Metab Pharmacokinet; 2018 Aug; 43(4):475-481. PubMed ID: 29332198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.